Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index; 5 of the 31 sources its claims cite were checked for support.

Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge

Open access
Hird, Thomas R., Grassly, Nicholas C. · 2012 · PLoS Pathogens

Abstract

Inactivated poliovirus vaccine (IPV) may be used in mass vaccination campaigns during the final stages of polio eradication. It is also likely to be adopted by many countries following the coordinated global cessation of vaccination with oral poliovirus vaccine (OPV) after eradication. The success of IPV in the control of poliomyelitis outbreaks will depend on the degree of nasopharyngeal and intestinal mucosal immunity induced against poliovirus infection. We performed a systematic review of studies published through May 2011 that recorded the prevalence of poliovirus shedding in stool samples or nasopharyngeal secretions collected 5-30 days after a "challenge" dose of OPV. Studies were combined in a meta-analysis of the odds of shedding among children vaccinated according to IPV, OPV, and combination schedules. We identified 31 studies of shedding in stool and four in nasopharyngeal samples that met the inclusion criteria. Individuals vaccinated with OPV were protected against infection and shedding of poliovirus in stool samples collected after challenge compared with unvaccinated individuals (summary odds ratio [OR] for shedding 0.13 (95% confidence interval [CI] 0.08-0.24)). In contrast, IPV provided no protection against shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59-1.11]) or when given in addition to OPV, compared with individuals given OPV alone (summary OR 1.14 [95% CI 0.82-1.58]). There were insufficient studies of nasopharyngeal shedding to draw a conclusion. IPV does not induce sufficient intestinal mucosal immunity to reduce the prevalence of fecal poliovirus shedding after challenge, although there was some evidence that it can reduce the quantity of virus shed. The impact of IPV on poliovirus transmission in countries where fecal-oral spread is common is unknown but is likely to be limited compared with OPV.

Overview

CoChat Summary

TL;DR

Systematic review and meta-analysis of poliovirus challenge studies found that OPV strongly reduces fecal poliovirus shedding after challenge, whereas IPV alone or added to OPV does not significantly reduce the prevalence of shedding. IPV may reduce the quantity and duration of virus shed, but evidence for nasopharyngeal mucosal protection was insufficient.

Key findings

  • OPV-vaccinated individuals were protected against poliovirus shedding in stool after challenge compared with unvaccinated individuals: summary OR 0.13 (95% CI 0.08–0.24).
  • IPV provided no significant protection against stool shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59–1.11]) or when added to OPV compared with OPV alone (summary OR 1.14 [95% CI 0.82–1.58]).
  • Direct comparison of OPV versus IPV schedules favored OPV: overall OR 0.15 (95% CI 0.08–0.27).
  • Five studies quantifying shedding found a 63%–91% (absolute 0.43–1.0 log10) reduction in mean quantity of poliovirus shed in stool among IPV-vaccinated compared with unvaccinated children; two of three studies examining duration found shorter shedding, and one study suggested combined quantity and duration reductions could reduce total virus shed by approximately 95%.
  • There were insufficient studies of nasopharyngeal shedding to draw a conclusion.

Methods

  • Systematic review of studies published through May 2011 identified via PubMed and Web of Knowledge, plus citation searching; 1,981 articles plus 6 additional studies were screened, yielding 31 stool-shedding studies and 4 nasopharyngeal-shedding studies meeting inclusion criteria.
  • Inclusion required recording prevalence of vaccine poliovirus shedding in stool or nasopharyngeal samples collected 5–30 days after a challenge dose of live-attenuated poliovirus; exclusions included duplicate findings, immunocompromised individuals, fewer than 30 individuals, insufficient serotype/schedule/shedding data, or challenge more than 5 years after vaccination.
  • Meta-analysis compared odds of shedding across vaccination categories—unvaccinated, trivalent OPV only, IPV only, and combined schedules—using fixed- or random-effects models according to heterogeneity, implemented in R with the rmeta package.

Limitations

  • The paper states there were insufficient nasopharyngeal shedding studies to draw conclusions, and that few samples were positive with insufficient power to compare vaccination histories.
  • The paper reports significant heterogeneity in some meta-analyses from variable sample timing, number/timing of vaccine doses, laboratory procedures, and unmeasured factors such as enteric infections; there were insufficient studies for a formal meta-regression.
  • The paper states there are no studies with adequate control populations investigating IPV impact on wild-type poliovirus transmission in areas with efficient fecal-oral transmission, and that challenge with high-titer Sabin poliovirus differs from natural wild-type exposure; the relationship between quantity shed and onward transmission is unknown.
  • Evident from the text: only 18 studies were included in the meta-analyses comparing vaccination histories, and only one study compared serotype 2 shedding in OPV-only versus OPV/IPV individuals, so no summary OR was calculated for that comparison.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1002599

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flow diagram showing included studies according to PRISMA guidelines [46]. The number of published articles identified by the given search term for initial screening and the resulting studies identified and included in the systematic review and meta-analysis are shown.
Figure 1 Flow diagram showing included studies according to PRISMA guidelines [46]. The number of published articles identified by the given search term for initial screening and the resulting studies identified and included in the systematic review and meta-analysis are shown.CC BY · PubMed Central
Figure 2 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with unvaccinated individuals. Odds ratios (ORs) and 95% confidence intervals for individual studies are indicated by the boxes and grey lines. The summary odds ratio for each serotype is given by a diamond with the 95% confidence interval (CI) indicated by its width. The χ2 test for heterogeneity among studies was significant for serotypes 2 and 3 (p-values 0.33, <0.001, and 0.001 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). Details of the studies included are given in Table S1. *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.
Figure 2 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with unvaccinated individuals. Odds ratios (ORs) and 95% confidence intervals for individual studies are indicated by the boxes and grey lines. The summary odds ratio for each serotype is given by a diamond with the 95% confidence interval (CI) indicated by its width. The χ2 test for heterogeneity among studies was significant for serotypes 2 and 3 (p-values 0.33, <0.001, and 0.001 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). Details of the studies included are given in Table S1. *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.CC BY · PubMed Central
Figure 3 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV compared with unvaccinated individuals. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was not significant for any serotype (p-values 0.11, 0.47, and 0.07) or for the overall odds ratio (p-value 0.10). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.
Figure 3 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV compared with unvaccinated individuals. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was not significant for any serotype (p-values 0.11, 0.47, and 0.07) or for the overall odds ratio (p-value 0.10). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.CC BY · PubMed Central
Figure 4 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with IPV. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was significant for serotypes 1 and 3 (p-values<0.001, 0.79, and 0.01 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.
Figure 4 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with IPV. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was significant for serotypes 1 and 3 (p-values<0.001, 0.79, and 0.01 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.CC BY · PubMed Central
Figure 5 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV in addition to OPV compared with individuals vaccinated with OPV only. Labeling as for Figure 2. The schedule indicates the number and type of OPV doses received by both groups and the number of doses of IPV that were added in the intervention group. In two studies, IPV was administered simultaneously with OPV at 6, 10, and 14 weeks (Modlin et al. 1997 [47] and du Chatelet et al. 2003 [48]), and in one study IPV was administered before and at the same time as OPV (schedule was IPV, IPV/OPV, OPV, OPV at 2, 4, 6, 15 months; WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines 1997 [49]). The χ2 test for heterogeneity among studies for serotypes 1 and 3 was not significant for each serotype (p-values 0.13 and 0.08) or for the serotypes combined (p-value 0.14).
Figure 5 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV in addition to OPV compared with individuals vaccinated with OPV only. Labeling as for Figure 2. The schedule indicates the number and type of OPV doses received by both groups and the number of doses of IPV that were added in the intervention group. In two studies, IPV was administered simultaneously with OPV at 6, 10, and 14 weeks (Modlin et al. 1997 [47] and du Chatelet et al. 2003 [48]), and in one study IPV was administered before and at the same time as OPV (schedule was IPV, IPV/OPV, OPV, OPV at 2, 4, 6, 15 months; WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines 1997 [49]). The χ2 test for heterogeneity among studies for serotypes 1 and 3 was not significant for each serotype (p-values 0.13 and 0.08) or for the serotypes combined (p-value 0.14).CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 1 Not valid · 19 Not checked · 25 Own results and interpretations

27 more claims

Create a free account to see all 49 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. G Enders-Ruckle, 1961, [Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle)]., Dtsch Med Wochenschr, 86, 1999

Cited by

See all 221

Metadata

Authors
Hird, T. R., & Grassly, N. C.
Affiliations
Imperial College London (GB)
Corresponding author
Grassly, Nicholas C.
Venue
PLoS Pathogens
Published
2012-04-19
Volume
8
Issue
4
Pages
e1002599
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W1971110767
Cited by
221
References
55
Citations by year
2026: 7 · 2025: 20 · 2024: 14 · 2023: 15 · 2022: 14 · 2021: 11 · 2020: 17 · 2019: 11 · 2018: 18 · 2017: 22 · 2016: 18 · 2015: 20 · 2014: 21 · 2013: 11 · 2012: 2
FWCI
2.83
Type
journal article
Language
en
Open access
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords
inactivated poliovirus vaccine, oral polio vaccine, mucosal immunity, intestinal immunity, polio eradication, vaccine challenge, fecal-oral transmission, poliomyelitis control
MeSH terms
Animals, Humans, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Virus Shedding, Poliovirus, Immunity, Mucosal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge. https://app.cochat.ai/papers/10.1371/journal.ppat.1002599
The paper
Hird, T. R., & Grassly, N. C. (2012). Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge. PLoS Pathogens. https://doi.org/10.1371/journal.ppat.1002599

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.